



Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes

Peter F. Thall¹, Yong Zang², Andrew G. Chapple³, Ying Yuan¹, Ruitao Lin¹, David Marin⁴, and Pavlos Msaouel^{5,6,7}

ABSTRACT

Conventional designs for choosing a dose for a new therapy may select doses that are unsafe or ineffective and fail to optimize progression-free survival time, overall survival time, or response/remission duration. We explain and illustrate limitations of conventional dose-finding designs and make four recommendations to address these problems. When feasible, a dose-finding design should account for long-term outcomes, include screening rules that drop unsafe or ineffective doses, enroll an adequate sample size, and randomize patients among doses. As illustrations, we review three designs that include one or more of these features. The first illustration is a trial that randomized patients among two cell therapy doses and standard of care in a setting where it was assumed on

biological grounds that dose toxicity and dose-response curves did not necessarily increase with cell dose. The second design generalizes phase I-II by first identifying a set of candidate doses, rather than one dose, randomizing additional patients among the candidates, and selecting an optimal dose to maximize progression-free survival over a longer follow-up period. The third design combines a phase I-II trial and a group sequential randomized phase III trial by using survival time data available after the first stage of phase III to reoptimize the dose selected in phase I-II. By incorporating one or more of the recommended features, these designs improve the likelihood that a selected dose or schedule will be optimal, and thus will benefit future patients and obtain regulatory approval.

Introduction

Preclinical development of new targeted and immunotherapy agents for cancers and other diseases has created a pressing need for clinical trials to evaluate and optimize these agents. Members of the medical research community have become aware that conventional methods for choosing the dose or schedule of a new agent are inadequate (1–6). Shah and colleagues (7) provided examples of several agents with recommended doses that had high toxicity rates in trials or postmarketing samples following FDA approval. Failure of conventional designs to reliably identify safe and effective doses apply generally, and they are likely to perform poorly for cytotoxics, radiotherapy, and targeted agents (2, 5, 7).

We review problems with conventional dose-finding designs and recommend desirable design features to obtain better results. We review three practical dose-finding designs that reliably identify safe doses that maximize progression-free survival (PFS) time, overall survival time (OS) time, or response/remission duration (RD). Our

goal is to motivate medical researchers to include these features in their dose-finding trials.

Background and Examples

The FDA initiated Project Optimus (7, 8), “to reform the dose optimization and dose selection paradigm in oncology drug development.” Despite widespread agreement that new dose-finding designs are needed for targeted or immunologic agents, it is unclear how to structure them for many medical settings. Conventional phase I designs choose a MTD by assigning doses to successive patient cohorts in a small trial using a 3+3 algorithm (9) or the continual reassessment method (CRM; refs. 10, 11), using dose-limiting toxicity (DLT) evaluated after one or two cycles of therapy. It is well known that a 3+3 algorithm is likely to produce poor decisions (2, 12, 13), with a high risk of an unacceptably high toxicity rate at the MTD in later trials (7, 13). Most phase I samples are too small to reliably choose an MTD or estimate its toxicity probability. For example, if two DLTs are observed in 6 patients treated at the MTD in phase I, a Bayesian posterior 95% credible interval for the probability of DLT at the MTD ranges from 8% to 71%. Treating an expansion cohort at the MTD does not solve this problem, because an MTD chosen based on a small sample has a high risk of being excessively toxic. Conventional designs assume that the risk of DLT increases with dose, “monotonicity”, which may be true for some agents but not others, and a careful analysis of all preclinical data should be done to adjudicate this before choosing a design. If the response probability is not monotone, dose escalation is inappropriate, because higher doses may be less safe or provide lower anticancer efficacy.

Conventional phase I designs ignore efficacy, such as tumor shrinkage or complete remission in cancers such as leukemias, which makes it impossible to choose doses based on risk-benefit trade-offs. Phase I-II designs use both toxicity and early efficacy to select doses and are well-known to be superior to phase I designs (2, 12, 13). Phase I-II designs accommodate dose-response curves with a plateau due to saturation of pharmacokinetic exposure in the patient, whereby the response rate does not increase for higher doses, and a selected dose on a plateau by conventional phase I designs may expose patients unduly

¹Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas.

²Department of Biostatistics and Health Data Science, Center for Computational Biology, and Bioinformatics, School of Medicine, Indiana University, Indianapolis, Indiana. ³Department of Interdisciplinary Oncology, School of Medicine, LSU Health Sciences Center, New Orleans. ⁴Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, Texas. ⁵Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas. ⁶Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ⁷David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Corresponding Author: Peter F. Thall, Department of Biostatistics, Unit 1411, The University of Texas MD Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402. E-mail: rex@mdanderson.org

Clin Cancer Res 2023;XX:XX-XX

doi: 10.1158/1078-0432.CCR-23-2222

©2023 American Association for Cancer Research

Translational Relevance

We address limitations of conventional trial early-phase designs that hinder clinical translation of promising new agents by choosing suboptimal doses. These designs may select doses that are either unsafe or ineffective and do not optimize outcomes such as progression-free survival time, overall survival time, or remission duration. We highlight four strategies to improve this process, which include accounting for long-term outcomes, excluding doses that are unsafe or ineffective, ensuring adequate sample size, and using randomization in dose selection. Three illustrative designs are discussed, each incorporating one or more of these recommendations. The examples provided underscore the potential of these methodologies to optimize the selected dose or schedule of a therapeutic intervention, thus enhancing patient outcomes and increasing the likelihood of securing regulatory approval. Such strategies, when effectively applied, could substantially improve dosage determination in oncology by maximizing long-term efficacy and patient safety.

to a higher risk of toxicity (2). For example, if five doses have toxicity probabilities 1%, 5%, 30%, 45%, and 50%, and response probabilities 20%, 50%, 50%, 50%, and 50%, a plateau is reached at dose 2. A 3+3 algorithm or CRM with target toxicity probability 30% both are most likely to select dose 3, while dose 2 has the same response probability of 50% but much lower toxicity probability of 5%. Although superior to conventional phase I, most phase I-II designs ignore PFS time, OS time, and RD evaluated over longer follow up. Because early outcomes seldom are reliable surrogates for long-term outcomes (14, 15), a dose chosen in phase I or phase I-II often fails to maximize PFS, OS, or RD (16, 17). **Table 1** gives examples and solutions provided by novel designs (1, 18–24). For example, writing R = response and T = toxicity, the phase I trial of niraparib for ovarian cancer in **Table 1** might be replaced by a phase I-II trial based on the utilities $U(R, \text{No } T) = 100$

and $U(\text{No } R, T) = 0$ for the best and worst possible outcomes, with $U(R, T) = 80$ and $U(\text{No } R, \text{No } T) = 40$ for the intermediate outcomes, using estimated values of U as a basis for evaluating doses. This could be extended further to use response duration to choose a best dose, by applying the generalized phase I-II design, described below.

As an illustration, a phase I trial of allogeneic stem cell transplantation for acute leukemia (25) studied six doses of vorinostat added to a standard preparative regimen, using the time-to-event CRM (26) with target toxicity probability 30%. Because very few DLTs were observed, the design rapidly escalated and selected the highest dose, level 6, as the MTD, where an expansion cohort was treated, giving per-dose sample sizes of 3, 3, 3, 4, 4, and 51. Longer follow up showed that patients treated with dose 6 had shorter OS than patients treated at doses 1–5. This effect persisted after accounting for prognostic variables (25, 27). Because dose 6 is undesirable, but a lower dose maximizing OS cannot be determined from the small samples at dose levels 1–5, it is unclear what dose to use in clinical practice, or how to design a future study. This trial suggests that, in general, longer term outcomes should be considered, along with toxicity and early response, when selecting a dose.

A second illustration is a phase I-II trial conducted to optimize the dose of sitravatinib, a tyrosine kinase inhibitor, + a fixed dose of nivolumab, an anti-programmed death agent, in clear cell renal cell carcinoma (ccRCC; ref. 1). The “Late Onset Efficacy-Toxicity (LO-ET) design (28) was used to choose among 60-, 80-, 120-, and 150-mg doses of sitravatinib, which had final respective LO-ET desirability scores of 0.622, 0.787, 0.755, and 0.630. However, longer outcomes including PFS time and later patient-reported outcomes measuring depression, quality of life, and hope for the future all indicated that the 120-mg dose was best, rather than the nominally optimal LO-ET dose of 80 mg (1).

Recommended Features of a Dose-Finding Design

To address limitations of conventional dose-finding methods, and respond to Project Optimus, we recommend that, when feasible

Table 1. Examples of flaws with conventional designs and solutions provided by novel designs.

| Disease | Agent | Design | References | Flaw | Solution |
|--|---|---|------------|---|--|
| Philadelphia chromosome-positive leukemias | Ponatinib (oral tyrosine kinase inhibitor) | 3+3 | 18, 19 | Pick an unsafe dose of 45 mg PO daily continuously (18), which later was modified to starting with 45 mg PO daily then 15 mg PO daily once $\leq 1\%$ <i>BCR-ABL</i> is achieved (19) | Include a dose toxicity rate safety monitoring rule |
| Non-small cell lung cancer | Onartuzumab (monoclonal antibody against MET) | 3+3 | 20, 21 | Pick a dose with a low response rate \rightarrow Phase III failure | Include a dose response rate utility monitoring rule |
| Ovarian Cancer | Niraparib (PARP inhibitor) | Accelerated titration 3+3 design | 22, 24 | Pick a dose with a high grade 3 hematologic toxicity rate | Account for toxicity grades and response using a utility function |
| High risk acute leukemias | Vorinostat (histone deacetylase inhibitor) | Time-to-event continual reassessment method (CRM) | 25 | Pick a dose that yielded a worse overall survival than the other doses. Limited sample size to choose among the other doses | Account for long-term overall survival and enroll adequate sample size for reliable dose selection |
| Clear cell renal cell carcinoma | Sitravatinib (oral tyrosine kinase inhibitor) in combination with nivolumab immunotherapy | Late-onset efficacy-toxicity | 1 | Unable to choose a dose giving better long-term survival | Account for long-term PFS or survival time when choosing a dose |

Table 2. Comparisons between the three dose-finding designs.

| Design | Sample size requirement ^a | Time requirement | Phases included | Advantages | Limitations | Recommended clinical scenarios |
|---|--------------------------------------|--|-----------------|---|---|---|
| Randomize all doses versus an active control and select the best dose | (K+1) n | Phase I–II | 1 + 2 | Unbiased dose-vs.-control comparisons. Can be expanded seamlessly to phase 3 | Appropriate if Pr (response) and Pr (toxicity) are not monotone in dose | Randomization of all doses versus an active control is acceptable and selecting an optimal dose is the goal |
| Gen 1–2 | K n + 10 m | Phase I–II + 10m more patients to estimate response/remission duration | 1 + 2 | Uses safety, response, and response/remission duration to optimize dose | Requires 10m more patients and 6 to 12 months longer follow up than phase 1–2 | A phase I–II trial is planned, including longer follow-up to assess duration of response/remission |
| Phase 1–2/3 | K n + phase 3 sample size | Phase I–II + Phase 1–II/III | 1 + 2 + 3 | Uses survival time to re-optimize the phase 1–2 dose and to do phase 3 comparison | Requires time and resources for conducting both phase 1–2 and phase 3. | A phase III trial is being considered, but better dose optimization is desired |

^aK = number of doses considered, n = average number of patients per dose in phase 1–2, m = number of candidate doses chosen in stage 2 of a Gen 1–2 trial.

depending on the setting, a dose-finding design should include one or more of the following features:

Feature 1. To choose an optimal dose, in addition to using short-term response and toxicity, a long-term outcome, such as PFS time, OS time, or RD, evaluated over longer follow up should be used.

Feature 2. Include screening rules that drop unsafe or ineffective doses. If some doses are dropped, enrich the sample sizes of remaining doses rather than reducing overall sample size.

Feature 3. Enroll a sample large enough to make reliable inferences.

Feature 4. If appropriate, randomize patients among doses and compare them with standard of care (SOC).

Feature 1 addresses the problem that early outcomes are imperfect surrogates for PFS, OS, or RD, so a dose-maximizing response rate often does not optimize long-term outcomes. Feature 1 requires longer follow-up, often 6 or 12 months, to evaluate the long-term outcome. Screening rules in Feature 2 protect patients from unsafe or ineffective doses, and enrichment increases dose selection reliability. Feature 3 is motivated by the fact that the precision of any inference increases with sample size. Feature 4 ensures that between-dose comparisons are fair and, to protect patient safety, a monitoring rule that stops accrual to an excessively toxic dose should be included.

Each of the following three designs has one or more of the recommended features. The randomized controlled selection design, which is well established, is the least complex. The other two designs are novel. The generalized phase I–II design has intermediate complexity, and the phase I–II/III design is most complex. Properties of these designs are summarized in **Table 2**, which may provide a basis for choosing among them in a particular setting.

A Randomized Controlled Selection Trial to Study Cellular Therapy in COVID-19

If assuming monotonicity is not valid, randomization is more appropriate because it gives unbiased comparisons between doses. The following study (29) used a three-arm randomized controlled design (16, 17) to select a best dose. This design is not new (19, 30), and it offers a scientifically attractive alternative to cohort-by-cohort dose-finding. The trial studied T-regulatory NK cells for treating COVID-19–related acute respiratory distress syndrome (ARDS; ref. 29). DLT

was any regimen-related grade 3 or worse toxicity within 48 hours of infusion, and response was defined as the patient being alive and extubated at day 28. Because there was no biological or medical reason to assume monotonicity, 45 patients were randomized to 10^8 cells, 3×10^8 cells, or SOC, with 15 patients per arm. DLT and response were coprimary outcomes, and OS was evaluated over longer follow up. Safety monitoring rules were included to shut down a dose showing excessive toxicity compared with SOC. A schematic of the trial is given in **Fig. 1**.

No toxicities were observed, and the response rate was highest for 10^8 cells (9/15, 60%) and SOC (9/15, 60%) and lowest for 3×10^8 cells (6/15, 40%) (29). Similarly, estimated 100-day survival probabilities were 86.2% for 10^8 cells, 77.9% for SOC, and 45.1% for 3×10^8 cells. Because a conventional phase I design would have escalated to the 3×10^8 cell arm, randomizing saved nearly 30 patients from being treated with the higher dose, 3×10^8 cells, which had the shortest estimated OS, and it prevented this dose from being selected.




Figure 1. Schematic of the randomized trial of cellular therapy for ARDS in COVID-19. Patients were randomly assigned to different doses of cellular therapy or standard of care.

This design is appropriate for any oncology trial of an agent when monotonicity in dose cannot be assumed. Two advantages of randomization are that the comparison between each dose of the agent and the active control is unbiased and, after the trial, patient cohorts treated with the selected dose or control may be expanded seamlessly to conduct a confirmatory randomized phase III trial, thus reducing phase III sample size. While two cell doses were considered in the COVID-19 ARDS trial, the randomized selection design is quite general. A larger number of doses, say K , may be included, and any endpoint may be used, subject to the practical requirement that the maximum sample size of $(K+1)n$ must be feasible, where n = number of patients per dose.

A Generalized Phase I-II Design to Optimize Response Duration

The following design extends phase I-II to include a long-term outcome. For many therapies, responders have a substantial risk of relapse. Clinical investigators aware of this problem often include a longer follow-up period in a phase I-II dose-finding trial protocol to estimate response/remission duration. A generalized phase I-II design, Gen 1-2, exploits this practice to identify a dose that maximizes the probability of long-term RD (27). The Gen 1-2 paradigm can incorporate any phase I-II design and tailor trials to accommodate a variety of clinical settings. Early outcomes may be binary or ordinal variables, such as toxicity grade and disease severity levels, and numerical utilities of (R,T) = (response, toxicity) may be used for choosing doses (2, 3, 31-35). A Gen 1-2 design schematic is given in Fig. 2.

To illustrate a Gen 1-2 design, let one month be the follow up to evaluate response and toxicity, with long-term therapeutic success defined as the patient being alive with stable disease or better at 6 months. Stages 1 and 2 consist of a phase I-II trial based on toxicity and response, including rules to drop any dose having an unacceptably high toxicity or low response rate. In stage 1, doses are assigned to patient cohorts using the phase I-II design's rules. Stage 2 randomizes patients among acceptable doses and identifies a set of nearly optimal candidate doses, rather than one dose. In stage 3, additional patients are randomized among the candidates, and all patients are followed to six months. The dose with largest six-month RD rate is selected as optimal. The stage 3 sample size is determined by computer simulation to obtain a desired level of reliability. Computer simulations showed that a Gen 1-2 design has optimal dose selection rates up to an order of magnitude larger than those of conventional phase I-II designs (27). Computer software for implementing a Gen 1-2 design is available from <https://github.com/yongzang2020>.

A Gen 1-2 design is being used for a trial of CAR-70 NK cells as targeted immunotherapy for solid tumors at MD Anderson Cancer Center (NCT05703854 at clinicaltrials.gov). Response and toxicity are evaluated in 1 month. To choose an optimal dose, responders are followed to estimate the probability of long-term success, defined as being alive and in remission at 6 months.

A Hybrid Seamless Phase I-II/III Design

Korn and colleagues (36) considered the timing of dose optimization in drug development, and recommended that it should be done during or after phase III. This solves the issues described above but produces the problem that reliably comparing the rates of an outcome among multiple doses and a control in phase III requires a large multi-arm trial. Seamless phase II-III designs (37-39) address this problem by combining randomized dose selection with confirmatory testing in




Figure 2.

Schematic of Gen 1-2 trial conduct. In stage 1, doses are assigned to successive patient cohorts using typical phase I-II design rules to optimize early efficacy and toxicity. The set of doses found to be acceptable during stage 1 then are randomly assigned among patients in stage 2 to select a set of acceptable doses and eliminate unacceptable doses more accurately. Additional patients then are randomized among the remaining acceptable doses and followed over an extended time period to establish efficacy in terms of long-term outcomes such as progression-free survival. The candidate dose with the best estimated long-term outcome is ultimately chosen.

a large-scale trial, with reliability defined by generalized power (GP), the probability of (i) selecting a truly optimal dose that provides a meaningful survival improvement over standard therapy, and (ii) concluding in a final test that the new agent at the selected dose is superior to the standard. GP quantifies how well the entire process of dose selection and comparative testing behaves.

Chapple and Thall (37) proposed a three-stage 'phase I-II/III' design that combines phase I-II and phase III in one trial. In stage 1, any phase I-II design based on response or toxicity may be used, with patients adaptively randomized among acceptably safe doses. A best acceptable dose is selected, and stage 2 begins with a phase III trial based on OS time, with patients randomized between a control and the new agent at the selected phase I-II dose. After a prespecified number of deaths in stage 2, dose is reoptimized to maximize estimated mean survival time, and phase III is completed with patients randomized between the control and the new agent at the re-optimized dose. A final treatment comparison is based on all response, toxicity, and survival time data (40). A phase I-II/III design schematic is given in Fig. 3.

Computer simulations showed that a phase I-II/III design is greatly superior to conducting phase III without re-optimizing dose (37). Across a range of scenarios, dose re-optimization increases GP by 9% to 73%, and provides a substantial increase in expected survival time for patients enrolled in the trial. The price of dose re-optimization is that a phase III trial with $N = 500$ patients may require 10 to 100 additional patients to do phase I-II/III. If eligibility criteria of the phase I-II and phase III cohorts differ, to account for heterogeneity so that patient prognosis is not conflated with dose effects, regression models for early response, toxicity, and survival time must be extended to




Figure 3.

Schematic of phase I–II/III trial conduct. A phase 1–2 design is conducted initially to select the optimal dose based on early efficacy and toxicity. A phase III design subsequently is activated with patients randomly assigned to either this dose or standard of care as a control therapy. After a prespecified number of long-term outcome events occur in both the treatment and control arms, dose is reoptimized to maximize estimated long-term outcome duration using data from patients enrolled in both the phase I–II and phase III stages. A final comparison is performed at the end of the trial using efficacy, toxicity, and long-term outcome data from all patients.

include prognostic covariates. A similar approach can be taken in a Gen 1–2 design by extending regression models for early response and RD to include covariates. The main elaboration for phase I–II/III is dose re-optimization and dose switching during phase III. The most demanding requirement is trial planning, which requires extensive computer simulations. A freely available software package, Phase123, to implement the design is available in an R package archive at <https://cran.r-project.org/web/packages/Phase123/>.

To use **Table 2** for choosing between the three designs in a given setting, one may compute each design's expected sample size and trial duration for particular design parameters. For example, if

$K = 4$ doses are to be studied, with on average $n = 15$ patients per dose, then the randomized controlled selection design would require up to $(4+1)15 = 75$ patients. The Gen 1–2 design would require $4 \times 15 + 10m = 70, 80, 90$, or 100 patients, respectively, if $m = 1, 2, 3$ or 4 candidate doses are chosen in stage 2. The phase I–II/III design would require up to $60 + (N = \text{phase III sample size})$ patients, where N varies with the phase III design. For anticipated accrual rate of 10 patients per month, the respective accrual durations would be approximately $75/10 = 7.5$ months for the randomized selection design, $70/10 = 7$ to $100/10 = 10$ months for Gen 1–2, and, if $N = 500$ for phase III, $60/10 + (10 \text{ to } 100)/10 + 500/10 = 57$ to 66 months for phase I–II/III, plus final additional follow up time added to each of these durations

Future Research

Many important issues remain, including evaluating schedules or (dose, schedule) combinations (41). A complex issue is how best to give a therapy repeatedly over multiple cycles, with later doses chosen based on each patient's previous doses and outcomes (42, 43). Additional challenges include accounting for late onset toxicity or response, and low-grade toxicities. A major issue is incorporating pharmacokinetic and pharmacodynamic parameters when evaluating doses, because the area under a pharmacokinetic curve quantifies systemic exposure for a given dose. This requires additional pharmacokinetic and pharmacodynamic analyses that may greatly complicate adaptive decision making during a trial. The ultimate goal is to choose personalized doses to account for patient heterogeneity (31–33, 44). Several designs for personalized dose-finding have been proposed (3, 45–48). Future research will integrate precision medicine approaches with the designs discussed here to incorporate information from long-term outcomes, use randomization to fairly compare doses, and conduct Gen 1–2 or phase I–II/III studies.

Authors' Disclosures

R. Lin reports personal fees from Merck Sharp & Dohme, ITM Oncologics GmbH, and personal fees from Monte Rosa Therapeutics outside the submitted work. P. Msaouel reports personal fees from Mirati Therapeutics, Bristol Myers Squibb, Exelixis, Pfizer, and Exelixis; grants from Takeda, and Bristol Myers Squibb; as well as grants from Mirati Therapeutics outside the submitted work; and Leadership or fiduciary roles as a Medical Steering Committee member for the Kidney Cancer Association and a Kidney Cancer Scientific Advisory Board member for KCCure. No disclosures were reported by the other authors.

Received July 26, 2023; revised August 25, 2023; accepted September 14, 2023; published first September 19, 2023.

References

- Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, et al. A phase 1–2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. *Sci Transl Med* 2022;14:eabm6420.
- Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding. *Ann Oncol* 2018;29:694–9.
- Lee J, Thall PF, Msaouel P. Precision Bayesian phase I–II dose-finding based on utilities tailored to prognostic subgroups. *Stat Med* 2021;40:5199–217.
- Yuan Y, Nguyen HQ, Thall PF. *Bayesian Designs for Phase I–II Clinical Trials*. Boca Raton, FL: CRC Press LLC; 2015.
- Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RM, Hong DS. Moving beyond 3+3: the future of clinical trial design. *Am Soc Clin Oncol Educ Book* 2021;41:e133–e44.
- Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. *J Clin Oncol* 2022;40:3489–500.
- Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology - when less is more. *N Engl J Med* 2021;385:1445–7.
- Murphy R, Halford S, Symeonides SN. Project optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. *Front Oncol* 2023;13:1144056.
- Storer BE. Design and analysis of phase I clinical trials. *Biometrics* 1989;45:925–37.
- Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, et al. How to design a dose-finding study using the continual reassessment method. *BMC Med Res Methodol* 2019;19:18.
- Yuan Y, Lee JJ, Hilsenbeck SG. Model-assisted designs for early-phase clinical trials: simplicity meets superiority. *JCO Precis Oncol* 2019;3:PO.19.00032.

12. Braun TM. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. *Control Clin Trials* 2002;23:240–56.
13. Thall P, Cook J. Dose-finding based on toxicity-efficacy trade-offs. *Biometrics* 2004;60:684–93.
14. Weir CJ, Taylor RS. Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments. *Pharm Stat* 2022;21:740–56.
15. Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. *J Clin Oncol* 2023;41:2706–12.
16. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. *Biometrics* 1998;54:251–64.
17. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. *J Clin Oncol* 1996;14:296–303.
18. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. *N Engl J Med* 2012;367:2075–88.
19. Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. *Blood* 2021;138:2042–50.
20. Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, et al. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. *Clin Cancer Res* 2014;20:1666–75.
21. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus? *Expert Rev Anticancer Ther* 2015;15:487–9.
22. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase I dose-escalation trial. *Lancet Oncol* 2013;14:882–92.
23. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med* 2016;375:2154–64.
24. Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, et al. Safety and dose modification for patients receiving niraparib. *Ann Oncol* 2018;29:1784–92.
25. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, et al. Vorinostat combined with busulfan, fludarabine, and clofarabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute leukemia: long-term study outcomes. *Transplant Cell Ther* 2022;28:501 e1–e7.
26. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. *Biometrics* 2000;56:1177–82.
27. Thall PF, Zang Y, Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. *Pharm Stat* 2023;22:692–706.
28. Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I-II clinical trials with delayed outcomes. *J Am Stat Assoc* 2014;109:525–36.
29. Gladstone DE, D'Alessio FR, Howard C, Lyu MA, Mock JR, Gibbs KW, et al. Randomized, double blinded, placebo controlled trial of allogeneic cord blood T-regulatory cell for treatment of COVID-19 ARDS. *Blood Adv* 2023;7:3075–9.
30. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. *Nat Med* 2013;19:329–36.
31. Msaouel P, Lee J, Thall PF. Making patient-specific treatment decisions using prognostic variables and utilities of clinical outcomes. *Cancers (Basel)* 2021;13:2741.
32. Lee J, Thall PF, Lim B, Msaouel P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. *J R Stat Soc Ser C Appl Stat* 2022;71:1605–22.
33. Lee J, Thall PF, Msaouel P. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. *Biometrics* 2022;79:2458–73.
34. Liu S, Guo B, Yuan Y. A Bayesian phase I/II trial design for immunotherapy. *J Am Stat Assoc* 2018;113:1016–27.
35. Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies. *JCO Precis Oncol* 2020;4:PO.20.00257.
36. Korn EL, Moscow JA, Freidlin B. Dose optimization during drug development: whether and when to optimize. *J Natl Cancer Inst* 2022;115:492–7.
37. Chapple AG, Thall PF. A hybrid phase I-II/III clinical trial design allowing dose re-optimization in phase III. *Biometrics* 2019;75:371–81.
38. Thall PF, Nguyen HQ, Wang X, Wolff JE. A Hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity. *J Stat Plan Inference* 2012;142:944–55.
39. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. *Biometrics* 2002;58:823–31.
40. Janne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle. *Clin Cancer Res* 2016;22:2613–7.
41. Guo B, Li Y, Yuan Y. A dose-schedule finding design for phase I-II clinical trials. *J R Stat Soc Ser C Appl Stat* 2016;65:259–72.
42. Lee J, Thall PF, Ji Y, Muller P. Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. *J Am Stat Assoc* 2015;110:711–22.
43. Fernandes LL, Taylor JM, Murray S. Adaptive phase I clinical trial design using Markov models for conditional probability of toxicity. *J Biopharm Stat* 2016;26:475–98.
44. Thall PF. Bayesian cancer clinical trial designs with subgroup-specific decisions. *Contemp Clin Trials* 2020;90:105860.
45. Thall PF. Bayesian utility-based designs for subgroup-specific treatment comparison and early-phase dose optimization in oncology clinical trials. *JCO Precis Oncol* 2019;3:PO.18.00379.
46. Lee J, Thall PF, Rezvani K. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times. *J R Stat Soc Ser C Appl Stat* 2019;68:461–74.
47. Guo B, Yuan Y. Bayesian phase I/II biomarker-based dose finding for precision medicine with molecularly targeted agents. *J Am Stat Assoc* 2017;112:508–20.
48. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. *Biometrics* 2008;64:1126–36.